Why the study?
Does recombinant thrombopoietin improve hematopoietic reconstitution in murine and nonhuman primate models of radiation-induced myelosuppression?
Population
Murine and nonhuman primate models of radiation-induced pancytopenia
Design
Preclinical
Authors
Loading...
May support TPO exploration in moderate radiation myelosuppression; leaves open efficacy after high-dose conditioning with stem cell rescue.
Does recombinant thrombopoietin improve hematopoietic reconstitution in murine and nonhuman primate models of radiation-induced myelosuppression?
Recombinant TPO is a potent therapeutic agent for counteracting radiation-induced pancytopenia in mid-lethal radiation models, though it appears ineffective following high-dose radiation with stem cell transplantation.
Wagemaker et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: